Overview of Remplir’s Real-World Evidence Study
Orthocell, a Perth-based company, has released new real-world data for its nerve repair product, Remplir. The results show a near-90% treatment success rate, supporting the company’s global commercial expansion. The latest findings come from an ongoing real-world evidence (RWE) study that includes 66 patients and 78 procedures. This marks a significant increase from the initial results in September 2025, which involved 33 participants.
The study covers a wide range of peripheral nerve conditions, including both acute traumatic injuries and chronic issues like carpal and cubital tunnel syndrome. These conditions can cause muscle paralysis, pain, numbness, and persistent tingling, often requiring surgical intervention. The results are consistent with earlier clinical data and published trial results, reinforcing the product’s effectiveness and safety profile.
Strong Outcomes in Motor Nerve Repair
Motor nerve repair procedures using Remplir showed a 90.3% success rate. Out of 31 repairs, 28 achieved functional muscle recovery. Patients were assessed using the British Medical Research Council (MRC) grading system, which evaluates muscle strength controlled by the repaired nerve.
These procedures primarily targeted patients with severe injuries such as tetraplegia and brachial plexus damage. The aim was to restore movement in the arm and hand. Success was defined as achieving MRC Grade M3 or M4, indicating voluntary movement with improved strength and range of motion.
In a subgroup of six tetraplegic patients (C4–C7 spinal cord injury), all nerve repairs resulted in functional recovery of a target muscle. This represents a clinically meaningful restoration of hand function for patients who previously had limited or no use of the affected limb.
Positive Results in Nerve Decompression Procedures
Remplir also demonstrated an 89.4% success rate in nerve decompression procedures. A total of 47 participants were assessed, including those undergoing carpal tunnel revision surgeries and cubital tunnel releases.
Patients with carpal tunnel revision had previously undergone decompression surgery but experienced persistent or recurrent symptoms. These symptoms included pain, weakness, and numbness, often linked to scar tissue or impaired nerve movement.
Results showed that 42 out of 47 procedures led to significant improvement or complete relief, with no patients requiring additional surgery during follow-up. This highlights the effectiveness of Remplir in addressing recurring nerve issues.
Growing Adoption and Commercial Expansion
Orthocell reports that the growing body of real-world evidence is driving increased adoption of Remplir across key markets. In Australia, over 300 surgeons across 220+ hospitals are using the product. In the US, more than 49 surgeons across 55+ hospitals have purchased Remplir.
The company aims to support further commercial growth, particularly in the US, where the rollout is ongoing, and in Europe, where regulatory approval is targeted for H2 CY26. The study was conducted in collaboration with clinicians and therapy providers across Western Australia, including Dr Alex O’Beirne, Associate Professor Matthew Lawson-Smith, and Jaslyn Cullen.
Future Prospects and Industry Impact
The results are expected to be presented at upcoming medical conferences as recruitment continues. Managing director Paul Anderson highlighted that these findings strengthen Remplir’s position as the best-performing nerve wrap available in Australia. He emphasized the strong and consistent clinical outcomes across a broad range of nerve repair procedures, supported by an excellent safety profile.
Orthocell believes the expanding dataset will continue to support surgeon adoption and commercial expansion in the US and other key markets. As the company moves forward, it remains committed to delivering high-quality solutions for nerve repair and improving patient outcomes globally.
